Role of Tim-3:Bat-3 pathway in inducing tolerogenic DCs and peripheral tolerance
Tim-3:Bat-3 通路在诱导耐受性 DC 和外周耐受中的作用
基本信息
- 批准号:9887786
- 负责人:
- 金额:$ 43.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-03 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:Adaptor Signaling ProteinAddressAffectAntibodiesAntigensAutoimmune DiseasesAutoimmunityBindingBiochemicalCD8B1 geneCell physiologyCell surfaceCellsCellular biologyChiropteraChronicClinicalClinical TrialsCommunicable DiseasesDataDendritic CellsDevelopmentExperimental Autoimmune EncephalomyelitisFunctional disorderGatekeepingGene FamilyGenerationsGenesGenetic TranscriptionGlutamatesHumanITGAX geneImmune responseImmunoglobulinsInflammationInflammatoryInsulin-Dependent Diabetes MellitusInterferon Type IIKnockout MiceLaboratoriesMacrophage ActivationMalignant NeoplasmsMediatingMolecularMucinsMultiple SclerosisMusMyelogenousMyeloid CellsPathogenicityPathologicPathway interactionsPhenotypePlayPopulationPredispositionProteinsProteomicsPsoriasisReportingResistanceRheumatoid ArthritisRoleSeriesSeveritiesSignal TransductionSignaling MoleculeT cell responseT-Cell DevelopmentT-LymphocyteTC1 CellTailTherapeuticTissuesTransducersTransforming Growth Factor betaTyrosineViralViral CancerVirus Diseasesbasecancer clinical trialconditional knockoutcytokinedensitydifferential expressioneffector T cellexhaustexhaustionexperimental studyhuman diseaseimmunoregulationin vivomacrophagemembernoveloverexpressionperipheral tolerance
项目摘要
PROJECT SUMMARY
We cloned TIM 3 as a molecule differentially expressed on IFN-g producing T cells and has emerged as a major
inhibitory molecule necessary for the termination of effector T cell responses. Tim 3 expression is increased on
effector T cells in human chronic viral infections and cancers, rendering them dysfunctional. In contrast, in human
autoimmune diseases, there is loss of Tim 3 expression on effector T cells, rendering them highly pro-
inflammatory and pathogenic. Because of its role in T cell exhaustion, Tim 3 is being targeted in multiple clinical
trials for cancer. Tim 3 is also expressed constitutively on dendritic cells (DCs), however, the role and function
of Tim 3 on DCs is not well understood and this is especially important to understand, in the view of clinical trials
that are underway with anti-Tim 3 antibodies.
As in T cells, Tim 3 is co-expressed in DCs with its adapter protein Bat-3, where Bat-3 acts as a molecular “gate-
keeper”, that restricts Tim 3 signaling and function. To understand the function of Tim 3 in DCs, we have
generated conditional “knock-out” mice of both Tim 3 and Bat-3 in DCs. Initial studies indicate that unrestricted
signaling of Tim 3 in the absence of Bat-3, makes Bat-3-deficient DCs tolerogenic such that they do not effectively
induce inflammatory T cell responses and the mice are resistant to development of autoimmunity. Based on our
preliminary data, we hypothesize that unabated Tim 3 signaling in DCs promotes generation of tolerogenic DCs.
To address this hypothesis, we propose two specific aims:
1. Determine how the Tim 3/Bat-3 interaction regulates development of tolerogenic DCs. We have observed
that unopposed signaling of Tim 3, by deleting Bat-3, specifically in DCs inhibits development of multiple
autoimmune diseases including Experimental Autoimmune Encephalomyelitis (EAE) which is the focus
of this proposal. Using conditional “knock-out” mice for both Tim 3 and Bat-3 in DCs, we propose to
determine whether resistance to autoimmunity in Bat-3 cKO mice is partly or completely restored by
deletion of Tim 3 from the same set of DCs. Furthermore, this will also allow us to determine how loss of
Bat-3 regulates DC phenotype and function.
2. Determine the molecular mechanism by which interaction of Tim 3 and the Smad/TGF-b pathway
promotes the generation of tolerogenic DCs. Using an unbiased proteomic screen to identify molecules
that bind to the Tim 3 tail in the absence of Bat-3, we identified Smad-2, a transducer of TGF-b pathway,
as a Tim 3 interacting protein. This novel observation allows us to study the mechanism by which Tim 3
mediates its inhibitory function, specifically we will be able to determine the molecular basis by which Tim
3/Smad/TGF-b pathway promotes the development of tolerogenic DCs. Using high density temporal
transcriptional analysis of the Tim 3 and Bat-3 deficient DCs, we propose to develop transcriptional
networks by which the Tim 3:Bat-3 pathway mediates its inhibitory function in DCs.
The proposed studies will identify how the Tim 3:Bat-3 pathway makes DCs tolerogenic, providing critical
information that could be exploited to benefit multiple human diseases. While repressing Tim 3 function could
augment immune responses in chronic viral infections and cancer, boosting Tim 3 signals could dampen
autoimmune diseases and promote antigen specific tolerance.
项目总结
我们克隆了TIM3作为一种在产生干扰素-g的T细胞上差异表达的分子,并且已经成为一种主要的
终止效应器T细胞反应所必需的抑制分子。TIM 3的表达增加
人类慢性病毒感染和癌症中的效应T细胞,使其功能障碍。相比之下,在人类中
自身免疫性疾病中,效应器T细胞上TIM3表达缺失,使其高度支持
炎症性和致病性的。由于其在T细胞衰竭中的作用,TIM 3正成为多个临床的靶点
癌症试验。TIM-3在树突状细胞(DC)上也有组成性表达,但其作用和功能
从临床试验的角度来看,TIM 3对DC的作用还不是很清楚,理解这一点尤其重要
正在用抗TIM 3抗体进行研究。
与在T细胞中一样,TIM 3与其适配蛋白BAT-3在DC中共表达,其中BAT-3起到分子“门-门”的作用。
Keeper“,这限制了TIM 3的信号和功能。为了了解TIM 3在DC中的功能,我们有
在DC中产生TIM 3和BAT-3的条件性“敲除”小鼠。初步研究表明,不受限制
在没有BAT-3的情况下,TIM 3的信号转导使BAT-3缺陷的DC具有耐受性,从而使它们不能有效地
诱导炎性T细胞反应,小鼠对自身免疫的发展具有抵抗力。基于我们的
初步数据显示,我们假设树突状细胞中TIM-3信号的未减弱促进了耐受树突状细胞的产生。
为了解决这一假设,我们提出了两个具体目标:
1.确定TIM 3/BAT-3相互作用如何调节致耐受树突状细胞的发育。我们观察到
TIM 3通过删除BAT-3,特别是DC中的非相反信号抑制多发性硬化的发展
包括实验性自身免疫性脑脊髓炎(EAE)在内的自身免疫性疾病是重点
这项提议。在DC中使用TIM 3和BAT-3的条件性“敲除”小鼠,我们建议
确定BAT-3 CKO小鼠对自身免疫的抵抗力是否部分或完全恢复
从同一组DC中删除TIM 3。此外,这也将使我们能够确定损失如何
BAT-3调节DC的表型和功能。
2.确定TIM-3与Smad/TGF-b途径相互作用的分子机制
促进产生耐受树突状细胞。使用无偏蛋白质组筛选来鉴定分子
在没有BAT-3的情况下,我们鉴定了Smad-2,它是转化生长因子-b途径的转导分子,
作为一种TIM-3相互作用蛋白。这一新颖的观察结果使我们能够研究TIM 3
介导其抑制功能,特别是我们将能够确定时间的分子基础
3/Smad/TGF-b途径促进耐受树突状细胞的发育。使用高密度时间
TIM 3和BAT-3缺陷DC的转录分析,我们建议发展转录
TIM3:BAT-3通路在DC中介导其抑制功能的网络。
拟议的研究将确定TIM 3:BAT-3途径如何使DC产生耐受,提供关键的
可以被利用来造福于多种人类疾病的信息。在抑制TIM 3功能的同时,
增强慢性病毒感染和癌症的免疫反应,增强TIM 3信号可能会抑制
自身免疫性疾病和促进抗原特异性耐受。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VIJAY K. KUCHROO其他文献
VIJAY K. KUCHROO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VIJAY K. KUCHROO', 18)}}的其他基金
Metabolic regulators of Treg/Th17 balance in CNS autoimmunity
CNS 自身免疫中 Treg/Th17 平衡的代谢调节因子
- 批准号:
10708996 - 财政年份:2022
- 资助金额:
$ 43.49万 - 项目类别:
Metabolic regulators of Treg/Th17 balance in CNS autoimmunity
CNS 自身免疫中 Treg/Th17 平衡的代谢调节因子
- 批准号:
10585009 - 财政年份:2022
- 资助金额:
$ 43.49万 - 项目类别:
Role of Tim-3:Bat-3 pathway in inducing tolerogenic DCs and peripheral tolerance
Tim-3:Bat-3 通路在诱导耐受性 DC 和外周耐受中的作用
- 批准号:
10333307 - 财政年份:2020
- 资助金额:
$ 43.49万 - 项目类别:
Proj 4: Triggers for the Induction of T Cell Dysfunction on T cells in Glioblastoma
项目 4:在胶质母细胞瘤中诱导 T 细胞功能障碍的触发因素
- 批准号:
10477988 - 财政年份:2020
- 资助金额:
$ 43.49万 - 项目类别:
Role of Tim-3:Bat-3 pathway in inducing tolerogenic DCs and peripheral tolerance
Tim-3:Bat-3 通路在诱导耐受性 DC 和外周耐受中的作用
- 批准号:
10094188 - 财政年份:2020
- 资助金额:
$ 43.49万 - 项目类别:
Proj 4: Triggers for the Induction of T Cell Dysfunction on T cells in Glioblastoma
项目 4:在胶质母细胞瘤中诱导 T 细胞功能障碍的触发因素
- 批准号:
10684037 - 财政年份:2020
- 资助金额:
$ 43.49万 - 项目类别:
Proj 4: Triggers for the Induction of T Cell Dysfunction on T cells in Glioblastoma
项目 4:在胶质母细胞瘤中诱导 T 细胞功能障碍的触发因素
- 批准号:
10210223 - 财政年份:2020
- 资助金额:
$ 43.49万 - 项目类别:
Role of Tim-3:Bat-3 pathway in inducing tolerogenic DCs and peripheral tolerance
Tim-3:Bat-3 通路在诱导耐受性 DC 和外周耐受中的作用
- 批准号:
10551198 - 财政年份:2020
- 资助金额:
$ 43.49万 - 项目类别:
Role of Tim-1 and Bregs in Tolerance and Autoimmunity
Tim-1 和 Bregs 在耐受性和自身免疫中的作用
- 批准号:
10214479 - 财政年份:2018
- 资助金额:
$ 43.49万 - 项目类别:
Role of Tim-1 and Bregs in Tolerance and Autoimmunity
Tim-1 和 Bregs 在耐受性和自身免疫中的作用
- 批准号:
10455068 - 财政年份:2018
- 资助金额:
$ 43.49万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 43.49万 - 项目类别:
Research Grant